News
Gut Wealth’s Gemma Stuart on turning science-led gut health into a scalable business
Gut Wealth’s Gemma Stuart on turning science-led gut health into a scalable business This month we caught up with Gemma Stuart, founder of Equity Gap portfolio company Gut Wealth – an Edinburgh-based business developing science-backed digestive
ULEMCO wins the Innovation Award for the North-West Region at the Small Business Growth Awards
Equity Gap are delighted to congratulate portfolio company, ULEMCo, on being recognised in the 2026 Small Business Growth Awards, delivered jointly by HSBC Commercial Banking and the Federation of Small Businesses. ULEMCo received the Innovation Award
EnteroBiotix secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
Equity Gap Portfolio, EnteroBiotix, has today announced the completion of a £19 million ($25 million) financing to advance EBX-102-02, its orally delivered investigational microbiome therapeutic, into Phase 2b development for Irritable Bowel Syndrome with Constipation (IBS-C).
Interpac receives Certificate of Grant for their US Patent
A significant milestone for Equity Gap portfolio company Interpac. We’re pleased to see Interpac secure both a US patent and an additional international patent from Taiwan, strengthening its global IP position and commercial potential. Interpac’s patented
MI:RNA shortlisted for 2026 Scottish Business of the Year Award
Equity Gap are delighted that their portfolio company, MI:RNA have been named on the innovation shortlist for the 2026 Scottish Business of the Year Awards. To be recognized alongside companies shaping the future of their industries
Vector Photonics wins at the University of Glasgow Knowledge Exchange & Innovation Awards
Equity Gap are delighted to congratulate Vector Photonics on winning the Champion Spin-out Award at the University of Glasgow Knowledge Exchange & Innovation Awards 2026. This recognition reflects not only technological innovation, but also the commitment,
SeaWarm’s Isabel DiPirro, Head of Operations & Sustainability, on market demand, commercialisation and national expansion
SeaWarm’s Isabel DiPirro, Head of Operations & Sustainability, on market demand, commercialisation and national expansion This month, we spoke to Isabel DiPirro, Head of Operations & Sustainability at Equity Gap portfolio company SeaWarm – a Scottish
EnteroBiotix has completed enrolment in a Phase 2a clinical trial
EnteroBiotix has completed enrolment in a Phase 2a clinical trial (called MAST). The trial is testing EBX-102-02, a microbiome-based therapy. It includes 50 adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). Patients receive either EBX-102-02